In Brief: J&J Health Care Systems
Executive Summary
J&J Health Care Systems: Chairman Dennis Longstreet was in error when he said at the Alex. Brown health care conference May 17 that Johnson & Johnson had a contract for managing quinolone use at Group Health of Puget Sound ("The Pink Sheet" May 22, p. 9). J&J had no such contract with Group Health or with any other managed care organization. J&J is said to have bid on a quinolone management contract for the Seattle-based HMO, but the bid was rejected. The J&J disease management group is performing antibiotic cost management in hospital settings, the company says...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth